Statins and primary prevention of VTE

In a follow-up study from the JUPITER trial (which randomized >17,000 older adults with LDL<130 and CRP >2 to rosuvastatin or placebo), after a median of 2 years, the rosuvastatin group had a lower risk of incident VTE (HR 0.57, CI 0.37-0.86). Although it would be premature to use statins for primary prevention of VTE, it is intriguing, and will likely results in studies evaluating the role of statins in preventing recurrent VTE (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment